Recce Pharmaceuticals (RCE) News Today → Urgent: Protect Your Investments from a Chinese Invasion (From Behind the Markets) (Ad) Free RCE Stock Alerts Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineRecce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP Portfoliofinance.yahoo.com - March 22 at 10:09 AMRecce hits milestone in Phase I/II trial for UTIs and urosepsismsn.com - March 19 at 10:30 PMRecce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsisfinance.yahoo.com - March 19 at 12:29 PMRecce Pharmaceuticals hits major milestone in R327 clinical trial for UTI/urosepsisproactiveinvestors.com.au - March 18 at 8:04 AMPleasing Signs As A Number Of Insiders Buy Recce Pharmaceuticals Stockfinance.yahoo.com - March 18 at 12:40 AMRecce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsisfinance.yahoo.com - March 14 at 8:55 AMRecce Pharmaceuticals to Present at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meetingfinance.yahoo.com - March 13 at 12:17 PMRecce Pharmaceuticals Receives AUD $11.17 Million Research and Development (R&D) Advancefinance.yahoo.com - March 12 at 12:43 PMRecce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research Institutefinance.yahoo.com - February 29 at 10:36 AMRecce Pharmaceuticals Announces Expansion of Phase I/II Trial of RECCE® 327 for the Treatment of Diabetic Foot Infectionsfinance.yahoo.com - February 27 at 12:00 PMRecce Pharmaceuticals Ltd (RCE.AX)au.finance.yahoo.com - February 9 at 2:44 AMRecce Pharmaceuticals Establishes Strategic Partnership in South-East Asia to Accelerate Clinical Programfinance.yahoo.com - February 7 at 8:29 AMRecce Pharmaceuticals Ltdafr.com - February 6 at 2:25 AMThose who invested in Recce Pharmaceuticals (ASX:RCE) five years ago are up 247%finance.yahoo.com - January 14 at 9:56 PMRecce Pharmaceuticals Awarded AusIndustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Programfinance.yahoo.com - December 19 at 11:48 AMRecce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 Against Gonorrheafinance.yahoo.com - December 18 at 12:21 PMRecce Pharmaceuticals awarded A$11 million Advanced Overseas Finding for anti-viral R&D costsau.investing.com - December 17 at 8:37 PMRecce Pharmaceuticals awarded $43.7 million Advanced Overseas Finding for synthetic anti-infective development programau.investing.com - December 14 at 1:26 AMRecce Pharmaceuticals achieves strong anti-bacterial effect against deadly Neisseria gonorrhoeae pathogen in animal modelau.investing.com - December 13 at 8:25 PMRecce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectivesfinance.yahoo.com - November 27 at 9:14 AMRecce Pharmaceuticals secures Canadian Patent for anti-infectivesproactiveinvestors.com - November 22 at 10:16 PMRecce Pharmaceuticals Completes Dosing First Subjects at 15-Minute Infusion Rate in a Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsisfinance.yahoo.com - November 9 at 10:12 AMIt's Unlikely That The CEO Of Recce Pharmaceuticals Ltd (ASX:RCE) Will See A Huge Pay Rise This Yearfinance.yahoo.com - November 1 at 7:50 PMRecce Pharmaceuticals presents at Ord Minnett Healthcare Forumproactiveinvestors.com.au - October 31 at 8:34 AMRecce Pharmaceuticals Announces Safety Committee Approves Faster Infusion Rate in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsisfinance.yahoo.com - October 25 at 8:10 AMRecce Pharmaceuticals welcomes safety committee approval of...Recce Pharmaceuticals welcomes safety committee approval of faster...proactiveinvestors.com.au - October 24 at 4:48 AMASX Health Stocks: Recce moves forward in Phase 1/2 study; EMV unveils Gen 2 helmet scanner for ambulancemsn.com - October 23 at 8:45 PMRecce Pharma says commercial potential of its anti-infectives is gaining recognitionfinance.yahoo.com - October 11 at 7:40 PMRecce Pharmaceuticals raises further funds to progress trials from entitlement shortfallproactiveinvestors.com - October 5 at 10:53 PMRecce Pharmaceuticals Announces Results of Entitlement Offerfinance.yahoo.com - October 3 at 12:40 PMRecce completes dosing of healthy subjects in UTI therapy trialmsn.com - September 28 at 8:09 AMRecce Pharmaceuticals Completes Dosing in Phase I/II Clinical Trial of RECCE® 327 for Urinary Tract Infectionsfinance.yahoo.com - September 26 at 1:38 PMRecce Pharmaceuticals demonstrates R327 safety profile at faster infusion rateproactiveinvestors.com - September 22 at 1:28 AMRecce Pharmaceuticals Secures $8M Placement and Launches $3M Entitlement Offer to Shareholdersfinance.yahoo.com - September 13 at 7:14 PMWhy is the Recce Pharmaceuticals share price collapsing 26% today?fool.com.au - September 11 at 2:05 AMRecce Pharmaceuticals secures $8 million in placement, launches $3 million entitlement offerproactiveinvestors.com.au - September 11 at 2:05 AMRecce Pharmaceuticals Provides Additional Positive Update on Patients Treated Under “Special Access Scheme”finance.yahoo.com - September 1 at 10:15 AMRecce Pharmaceuticals makes strides with R327G drug in multiple antibiotic-resistant infection casesproactiveinvestors.com - September 1 at 12:05 AMRecce Pharmaceuticals Announces Safety Committee Approves Next Dose of RECCE® 327 at 3,000mg in Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trialfinance.yahoo.com - August 29 at 6:27 PMRecce receives approval for next cohort dosing in UTI therapy trialmsn.com - August 28 at 9:30 PMRecce Pharmaceuticals Doses Patients in Phase I/II Clinical Trial of RECCE® 327 for Diabetic Foot Infectionsfinance.yahoo.com - August 24 at 7:05 PMRecce Pharma begins dosing in diabetic foot infection trialfinance.yahoo.com - August 23 at 4:05 PMRecce Pharmaceuticals Completes Stage 1 Data Analysis of Phase I/II Clinical Trial for the Treatment of Burn Wound Infectionsfinance.yahoo.com - August 23 at 9:46 AMRecce Pharmaceuticals successfully treats deadly burn infections...proactiveinvestors.com - August 21 at 3:25 AMRecce Pharmaceuticals successfully treats deadly burn infections in Phase I/II clinical trialproactiveinvestors.com.au - August 21 at 3:25 AMRecce Pharmaceuticals provides new hope in fight against superbugsfinance.yahoo.com - August 10 at 1:44 PMRecce Pharmaceuticals Provides Positive Update on Patients Treated with RECCE® 327 Under "Special Access Scheme"technews.tmcnet.com - August 10 at 8:44 AMRecce Pharmaceuticals Provides Positive Update on Patients Treated with RECCE® 327 Under “Special Access Scheme”finance.yahoo.com - August 10 at 8:44 AMRecce Pharmaceuticals welcomes positive case studies and research data for R327 gel formulation; shares upau.investing.com - August 8 at 8:56 AMInvestors might be losing patience for Recce Pharmaceuticals' (ASX:RCE) increasing losses, as stock sheds 15% over the past weekfinance.yahoo.com - August 8 at 8:56 AM Get Recce Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RCE and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem. Protect your retirement savings from the inevitable devaluation of the dollar… RCE Media Mentions By Week RCE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RCE News Sentiment▼1.740.60▲Average Medical News Sentiment RCE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RCE Articles This Week▼11▲RCE Articles Average Week Get Recce Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RCE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Algernon Pharmaceuticals News Today ALK-Abelló A/S News Today Alpha Tau Medical News Today Arno Therapeutics News Today Artelo Biosciences News Today Ascletis Pharma News Today Avacta Group News Today Awakn Life Sciences News Today AXIM Biotechnologies News Today BerGenBio ASA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:RCE) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recce Pharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.